William Summers, MD
Internal Medicine · Saint Louis, MONPI 1265471650
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,081 of the $92,559 with a category attached, or 74.6%. Gilead accounts for 96.6% of it on its own, with 23 other manufacturers making up the rest. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 472 payments — averaging $196.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$89K
- Viiv Healthcare Company$1K
- AstraZeneca$382
- AbbVie$283
- GSK$244
- Novo Nordisk$241
- plus $758 from 18 others
What the payments were for
- Consulting fees$1,2101%
- Speaking & faculty fees$69,08175%
- Travel & lodging$15,28917%
- Food & beverage$6,8687%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 253 | $89,371 |
| Viiv Healthcare Company | 102 | $1,281 |
| AstraZeneca | 22 | $382 |
| AbbVie(2 entities) | 24 | $283 |
| GSK | 17 | $244 |
| Novo Nordisk | 14 | $241 |
| Astellas Pharma US Inc | 4 | $96 |
| Johnson & Johnson | 4 | $93 |
| EMD Serono, Inc. | 3 | $74 |
| Lundbeck LLC | 3 | $69 |
| Merck | 4 | $61 |
| Pfizer | 3 | $54 |
| Antares Pharma, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Exact Sciences | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 3 | $30 |
| Lilly USA, LLC | 2 | $30 |
| Abbott | 1 | $28 |
| Theratechnologies Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Halozyme Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$92,559 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 837 | $3,299,613 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 91 | $388,195 |
| SerostimSomatropin | 14 | $286,301 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 51 | $188,696 |
| DescovyEmtricitabine/Tenofov Alafenam | 76 | $169,026 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 208 | $145,700 |
| JulucaDolutegravir/Rilpivirine | 40 | $143,486 |
| OzempicSemaglutide | 130 | $142,707 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 35 | $126,453 |
| Egrifta SvTesamorelin Acetate | 16 | $110,392 |
| FarxigaDapagliflozin Propanediol | 155 | $100,586 |
| OxycontinOxycodone Hcl | 53 | $75,058 |
| TivicayDolutegravir Sodium | 34 | $73,384 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $67,110 |
| MounjaroTirzepatide | 56 | $63,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $89,371 | $3,856,8341,004 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Tivicay, Dovato | $1,281 | $472,677149 claims |
| EMD Serono, Inc.Serostim | $74 | $286,30114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $244 | $190,074300 claims |
| Novo NordiskOzempic, Rybelsus | $241 | $168,669148 claims |
| Theratechnologies Inc.Egrifta Sv | $22 | $110,39216 claims |
| MerckDelstrigo, Januvia, Isentress, Pifeltro, Janumet | $61 | $109,73591 claims |
| Lilly USA, LLCMounjaro, Trulicity | $30 | $106,11490 claims |
| AstraZenecaFarxiga | $382 | $100,586155 claims |
| PfizerSelzentry, Eliquis | $54 | $73,44671 claims |
| Johnson & JohnsonXarelto | $93 | $29,42839 claims |
| AbbVieVraylar | $283 | $24,76718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
- Uladzislau NaidzionakSaint Louis$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.